Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

INSPIRE Pipeline™ Shield Post Approval Study

NCT05071963 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.

Conditions Studied

Interventions

  • DEVICE Treatment of Intracranial Aneurysms

Study Locations (16)

New York

  • NYU Langone Medical Center — New York
  • Montefiore Medical Center — New York

Pennsylvania

  • Geisinger Medical Center — Danville
  • Hospital of the University of Pennsylvania — Philadelphia

Alabama

  • University of Alabama at Birmingham — Birmingham

Connecticut

  • Yale New Haven Hospital — New Haven

Florida

  • Baptist Medical Center Jacksonville — Jacksonville

Georgia

  • Emory University Hospital — Atlanta

Illinois

  • Endeavor Health - Evanston Hospital — Evanston

Kentucky

  • Norton Healthcare — Louisville

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2021-12-20
Est. Completion 2028-04

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05071963

The ClinicalTrials.gov registry entry for NCT05071963 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Intracranial Aneurysm appearing as the primary indexed condition, and to 1 intervention — of which Treatment of Intracranial Aneurysms is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05071963 reports 16 study locations spanning 14 distinct geographic areas — top geographies include New York, Pennsylvania, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05071963 about?

NCT05071963 is a clinical study titled "INSPIRE Pipeline™ Shield Post Approval Study". The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pip...

What is the current status of trial NCT05071963?

This trial is currently active not recruiting. The enrollment target is 246 participants. The study started on 2021-12-20. Estimated completion is 2028-04.

What conditions does trial NCT05071963 study?

This clinical trial studies the following conditions: Intracranial Aneurysm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05071963?

The interventions under investigation include: Treatment of Intracranial Aneurysms (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05071963?

This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05071963 being conducted?

This trial has 16 study locations across Alabama, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial